Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes

Growth Factors

Volumn 31, Issue 2, 2013, Pages 66-73

  Shih, Kuang Chung ^a,b   Hsieh, Sheng Hwu ^c   Kwok, Ching Fai ^a,d   Hwu, Chii Min ^a,d   Hsieh, Po Shiuan ^e   Ho, Low Tone ^a,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Dawn phenomenon; Growth hormone; Insulin sensitivity; Octreotide; Type 2 diabetes mellitus

Indexed keywords

FATTY ACID; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN GROWTH HORMONE; INSULIN; OCTREOTIDE; PIG INSULIN; SODIUM CHLORIDE; SOMATOMEDIN C; SOMATOSTATIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; FATTY ACID BLOOD LEVEL; FEMALE; FLUOROMETRY; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GROWTH HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INFUSION RATE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; METABOLIC CLEARANCE RATE; MICROPARTICLE ENZYME IMMUNOASSAY; MORNING HYPERGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOMITING;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG CHRONOTHERAPY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; MALE; OCTREOTIDE;

EID: 84876238573     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2013.772996     Document Type: Article

References (33)

1. Atiea JA, Vora JP, Owens DR, Luzio S, Read GF, Walker RF, Hayes TM. 1988. Non-insulin-dependent diabetic patients (NIDDMs) do not demonstrate the dawn phenomenon at presentation. Diabetes Res Clin Pract 5:37-44.
2. Beebe CA, Van Cauter E, Shapiro ET, Tillil H, Lyons R, Rubenstein AH, Polonsky KS. 1990. Effect of temporal distribution of calories on the diurnal patterns of glucose levels and insulin secretion in NIDDM. Diabetes Care 13:748-755.
3. Boden G, Chen X, Urbain JL. 1996. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 45: 1044-1050.
4. Bolli GB, Gerich JE. 1984. The "dawn phenomenon"-A common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 310:746-750.
5. Bright GM, Melton TW, Rogol AD, Clarke WL. 1980. Failure of cortisol blockade to inhibit early morning increases in basal insulin requirements in fasting insulin-dependent diabetics. Diabetes 29:662-664.
6. Campbell PJ, Bolli GB, Cryer PE, Gerich JE. 1985. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. New Engl J Med 312:1473-1479.
7. Campbell PJ, Bolli GB, Gerich JE. 1988. Prevention of the dawn phenomenon (early morning hyperglycemia) in insulin dependent diabetes mellitus by bedtime intranasal administration of long acting somatostatin analog. Metabolism 37:34-37.
8. Carroll MF, Shade DS. 2005. The dawn phenomenon revisited: Implications for diabetes therapy. Endocr Pract 11:55-64.
9. Davies RR, Miller M, Turner SJ, Watson M, McGill A, Orskov H, Alberti KG, Johnston DG. 1986. Effects of somatostatin analogue SMS, 201-995 in non-insulin-dependent diabetes. Clin Endocrinol 25:739-747.
10. Davies RR, Turner SJ, Alberti KG, Johnston DG. 1989. Somatostatin analogues in diabetes mellitus. Diabet Med 6: 103-111.
11. DeFronzo RA, Tobin JD, Andres R. 1979. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223.
12. Domenici FP, Argentino DP, Munoz MC, Miquet JG, Sotelo AI, Turyn D. 2005. Influence of the crosstalk between growth hormon and insulin signaling on the modulation of insulin sensitivity. Growth Horm IGF Res 15:324-336.
13. Dux S, White NH, Skor DA, Santiago JV. 1985. Insulin clearance contributes to the variability of nocturnal insulin requirement in insulin-dependent diabetes mellitus. Diabetes 34:1260-1265.
14. Fineberg S, Merimee TJ. 1974. Acute metabolic effects of human growth hormone. Diabetes 23:499-504.
15. Gormsen LC, Nielsen C, Jessen N, Jørgensen JO, Møller N. 2011. Time-course effects of physiological free fatty aid surges on insulin sensitivity in humans. Acta Physiol (Oxf) 201:349-356.
16. Herlihy OM, Perros P. 2000. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes Metab Res Rev 16:211-216.
17. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Chen YD, Reaven GM. 1990. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 7:31-34.
18. Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT. 1997. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 82:3285-3292.
19. Jørgensen JO. 1991. Human growth hormone replacement therapy: Pharmacological and clinical aspects. Endocr Rev 12:189-207.
20. Krusenstjerna-Hafstrøm T, Clasen BF, Møller N, Jessen N, Pedersen SB, Christiansen JS, Jørgensen JO. 2011. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab 96:2548-2557.
21. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jørgensen JO. 2007. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92: 1724-1728.
22. MacGorman LR, Rizza RA, Gerich JE. 1981. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 53:556-559.
23. Møller N, Jorgensen JO. 2009. Effects of growth hormone on glucose, lipid and protein metabolism in human subjects. Endocr Rev 30:152-177.
24. Noma A, Okabe H, Kita M. 1973. A new colorimetric micro-determination of free fatty acids in serum. Clin Chim Acta 43: 317-320.
25. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. 1990. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52-59.
26. Rybicka M, Krysiak R, Okopién B. 2011. The dawn phenomenon and the Somogyi effect-two phenomena of morning hypergly-cemia. Endokrynol Pol 62:276-284.
27. Sassin JF, Parker DC, Mace JW, Gotlin RW, Johnson LC, Rossman LG. 1969. Human growth hormone release: Relation to slow-wave sleep and sleep-walking cycles. Science 165: 513-515.
28. Schmidt MI, Lin QX, Gwynne JT, Jacobs S. 1984. Fasting early morning rise in peripheral insulin: Evidence of the dawn phenomenon in nondiabetes. Diabetes Care 7:32-35.
29. Shih KC, Ho LT, Kou HF, Liu PC, Hsiao LC, Li SH, Liu YF, Wu MS. 1992. Diurnal variation in insulin sensitivity in NIDDM patients and normal subjects. J Formos Med Assoc 91:263-269.
30. Shih KC, Liu LY, Kwok CF, Hwu CM, Juan CC, Hsu YP, Ho LT. 2007. Effect of reversing dark-light cycles on normal diurnal variation and related metabolic disturbance in rats. Chin J Physiol 50:69-76.
31. Skor DA, White NH, Thomas L, Shah SD, Cryer PE, Santiago JV. 1983. Examination of the role of the pituitary-adrenocortical axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Diabetes 32:403-407.
32. Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR. 1988. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus. Horm Metab Res 20:168-170.
33. Xu J, Messina JK. 2009. Crosstalk between growth hormone and insulin signaling. Vitam Horm 80:125-153.